CN113144194A - 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 - Google Patents
一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 Download PDFInfo
- Publication number
- CN113144194A CN113144194A CN202110148016.7A CN202110148016A CN113144194A CN 113144194 A CN113144194 A CN 113144194A CN 202110148016 A CN202110148016 A CN 202110148016A CN 113144194 A CN113144194 A CN 113144194A
- Authority
- CN
- China
- Prior art keywords
- cov
- sars
- pneumonia
- use according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
GP73 siRNA | 序列5’-3’ |
siCtrl(SEQ ID No:1) | AUCACACCAACACAGGUCCTT |
SEQ ID No:1 | 275-CCUGGUGGCCUGUGUUAUUTT |
SEQ ID No:2 | 553-GCGAGAAGCUCAUUCGAGATT |
SEQ ID No:3 | 950-GCAGAAUGAGGAAACCAAUTT |
SEQ ID No:4 | 995-CCAACAGGCAUCCAUCCAATT |
SEQ ID No:5 | 1198-CAGGAGAUGAAUACGACAUTT |
SEQ ID No:6 | 1263-GCAGGGAAUGACAGAAAUATT |
SEQ ID No:7 | 1430-UGUGAAAUGGACAGCGAAATT |
SEQ ID No:8 | 1802-GCUCUUACCGUCAGCAUAATT |
SEQ ID No:9 | 2108-GCACCUAUGGUCUGUGUUUTT |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110148016.7A CN113144194B (zh) | 2021-02-03 | 2021-02-03 | 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110148016.7A CN113144194B (zh) | 2021-02-03 | 2021-02-03 | 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113144194A true CN113144194A (zh) | 2021-07-23 |
CN113144194B CN113144194B (zh) | 2021-12-14 |
Family
ID=76882703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110148016.7A Active CN113144194B (zh) | 2021-02-03 | 2021-02-03 | 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113144194B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023006127A1 (zh) * | 2021-07-28 | 2023-02-02 | 北京舜景生物医药技术有限公司 | Gp73作为非肥胖型非酒精性脂肪性肝病的治疗靶标、诊断标志物的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935822A (en) * | 1995-03-21 | 1999-08-10 | The Regents Of The University Of Colorado | Product and process for membrane and soluble polypeptide segregation |
CN1450164A (zh) * | 2003-06-11 | 2003-10-22 | 复旦大学 | 一种新型冠状病毒株及其医药用途 |
CN104940901A (zh) * | 2015-07-07 | 2015-09-30 | 中国人民解放军军事医学科学院生物工程研究所 | ERRα及其抑制剂在促进干扰素生成以及抑制病毒感染中的用途 |
CN110951756A (zh) * | 2020-02-23 | 2020-04-03 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN111450097A (zh) * | 2020-02-27 | 2020-07-28 | 中国人民解放军军事科学院军事医学研究院 | Abl酪氨酸激酶抑制剂在制备治疗冠状病毒所致疾病的药物中的应用 |
CN112111489A (zh) * | 2020-06-23 | 2020-12-22 | 深圳罗兹曼国际转化医学研究院 | 抑制SARS-COV-2病毒复制的shRNA及其应用 |
CN112121168A (zh) * | 2020-04-09 | 2020-12-25 | 中国人民解放军军事科学院军事医学研究院 | 一种抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 |
-
2021
- 2021-02-03 CN CN202110148016.7A patent/CN113144194B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935822A (en) * | 1995-03-21 | 1999-08-10 | The Regents Of The University Of Colorado | Product and process for membrane and soluble polypeptide segregation |
CN1450164A (zh) * | 2003-06-11 | 2003-10-22 | 复旦大学 | 一种新型冠状病毒株及其医药用途 |
CN104940901A (zh) * | 2015-07-07 | 2015-09-30 | 中国人民解放军军事医学科学院生物工程研究所 | ERRα及其抑制剂在促进干扰素生成以及抑制病毒感染中的用途 |
CN110951756A (zh) * | 2020-02-23 | 2020-04-03 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN111450097A (zh) * | 2020-02-27 | 2020-07-28 | 中国人民解放军军事科学院军事医学研究院 | Abl酪氨酸激酶抑制剂在制备治疗冠状病毒所致疾病的药物中的应用 |
CN112121168A (zh) * | 2020-04-09 | 2020-12-25 | 中国人民解放军军事科学院军事医学研究院 | 一种抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 |
CN112111489A (zh) * | 2020-06-23 | 2020-12-22 | 深圳罗兹曼国际转化医学研究院 | 抑制SARS-COV-2病毒复制的shRNA及其应用 |
Non-Patent Citations (6)
Title |
---|
CONGWEN WEI,等: "Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies", 《MEDRXIV》 * |
CONGWEN WEI,等: "HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry", 《NATURE METABOLISM》 * |
LUMING WAN,等: "GP73 is a glucogenic hormone regulating SARS-CoV-2-induced hyperglycemia", 《MEDRXIV》 * |
RALEIGH D.KLADNEY,等: "P73, a novel Golgi-localized protein upregulated by viral infection", 《GENE》 * |
YANG, X., 等: "Gp73, a novel tgf-β target gene, provides selective regulation on smad and non-smad signaling pathways", 《BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - MOLECULAR CELL RESEARCH》 * |
刘兴辉,等: "乙型肝炎病毒对高尔基体糖蛋白-73表达的影响研究", 《中国卫生检验杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023006127A1 (zh) * | 2021-07-28 | 2023-02-02 | 北京舜景生物医药技术有限公司 | Gp73作为非肥胖型非酒精性脂肪性肝病的治疗靶标、诊断标志物的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113144194B (zh) | 2021-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | miR-30a negatively regulates TGF-β1–induced epithelial-mesenchymal transition and peritoneal fibrosis by targeting Snai1 | |
CN107075515B (zh) | C/EBPα组合物和使用方法 | |
US20210139997A1 (en) | Treatment of angiogenesis disorders | |
US11197890B2 (en) | Methods of treating cancer, infectious disease, and autoimmune disease using CXC chemokines | |
WO2014122660A1 (en) | Cd14 inhibitors as an effective treatment for hcv infection | |
CN112543809A (zh) | 包含C/EBPα saRNA的组合疗法 | |
CN114410588A (zh) | 一种α1β1整合素依赖增强型CAR巨噬细胞及其制备方法和应用 | |
WO2018193902A1 (ja) | マイクロrnaによるb型肝炎ウイルスに対する抗ウイルス効果 | |
CN113144194B (zh) | 一种GP73抑制剂在制备治疗SARS-CoV-2肺炎及其并发症的药物中的应用 | |
CN114585384A (zh) | 使用C/EBPα saRNA的组合物和方法 | |
CN108753773A (zh) | 干扰IFN-gama表达的CD19-CAR-T细胞及其应用 | |
WO2015120434A1 (en) | Treatment of neurodegenerative and neurodevelopmental diseases by inhibition of the a2-na/k atpase/a-adducin complex | |
Trojan et al. | Neoplastic brain, glioblastoma, and immunotherapy | |
CN111803646B (zh) | 一种实体肿瘤联合治疗组合物 | |
WO2018042207A1 (en) | Treatment and prevention of viral infection | |
CN111433360B (zh) | 靶向ckip-1的双链rna分子及其用途 | |
KR101291953B1 (ko) | 톨라이크리셉터―8 유전자의 발현을 억제하는 작은 간섭rna 및 이를 함유하는 아토피성 피부염 치료용 조성물 | |
CN102056631B (zh) | 细胞凋亡诱导物 | |
EP2370092A1 (en) | Modulation of olfml-3 mediated angiogenesis | |
Park et al. | Antiviral effects of miRNAs in extracellular vesicles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mutations in SARS-CoV-2 RNA virus | |
CN117264948B (zh) | 抑制血管紧张素原基因表达的RNAi抑制剂及其应用 | |
KR101525229B1 (ko) | Gpr171 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물 | |
CN110891603A (zh) | 用于治疗肠道病毒感染的组合物和方法 | |
Wang et al. | Exosomes synthesizing HER2 miRNA and engineered to adhere to HER2 on surface tumor cells exhibit enhanced anti-tumor activity | |
WO2023033050A1 (ja) | ボルナウイルスベクターを利用した医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wei Congwen Inventor after: Wan Luming Inventor after: Zhong Hui Inventor after: Zhang Yanhong Inventor after: Gao Qi Inventor after: Huang Linfei Inventor after: Yang Xiaopan Inventor after: Lin Changqing Inventor after: Sun Zhiwei Inventor before: Wei Congwen Inventor before: Zhang Yanhong Inventor before: Wan Luming Inventor before: Zhong Hui Inventor before: Gao Qi Inventor before: Huang Linfei Inventor before: Yang Xiaopan Inventor before: Lin Changqing Inventor before: Sun Zhiwei |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |